ROCKWELL MEDICAL, INC.
RMTI evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for RMTI—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · RMTI
Rockwell Medical, Inc. is a commercial-stage company focused on hemodialysis concentrates, with a recent net loss and a cash position management believes sufficient for at least twelve months.
Key risk: Ongoing net losses
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Market Cap
$32.9M
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Jun 30, 2026.
Rockwell Medical, Inc. is a commercial-stage company focused on hemodialysis concentrates, with a recent net loss and a cash position management believes sufficient for at least twelve months.
- As of June 30, 2026, Rockwell Medical had approximately $24.8 million in cash, cash equivalents and investments available-for-sale, and net working capital of $25.2 million [sec_mda · as of 2026-08-13].
- For the six months ended June 30, 2026, the company reported total revenue of $17.8 million and a net loss of $1.2 million [latest reported financials (as of 2026-06-30)].
- Management believes the company has sufficient funds to meet operating requirements for at least the next twelve months from the filing date of the August 2026 report [sec_mda · as of 2026-08-13].
- The company's long-term funding is highly dependent on executing its hemodialysis concentrates growth strategy, achieving sustained profitability, and developing its product portfolio [sec_mda · as of 2026-08-13].
What works
- Rockwell Medical has a commercial hemodialysis concentrates business with existing customers, providing a revenue base of $17.8 million for the six months ended June 30, 2026 [latest reported financials (as of 2026-06-30)].
- The company has access to an at-the-market (ATM) facility with $13.1 million remaining availability, offering a potential source of additional capital [sec_mda · as of 2026-05-07].
- Management believes current working capital is sufficient to fund operations for at least the next twelve months, indicating near-term liquidity [sec_mda · as of 2026-08-13].
What to weigh
- Rockwell Medical reported a net loss of $1.2 million for the six months ended June 30, 2026, and has an accumulated deficit, reflecting ongoing unprofitability [latest reported financials (as of 2026-06-30)].
- The company's ability to fund long-term activities is subject to significant risks, including executing its growth strategy and achieving sustained profitability, with no assurance of success [sec_mda · as of 2026-08-13].
- If the company fails to raise additional capital on acceptable terms, it may be forced to curtail activities or cease operations [sec_mda · as of 2026-03-26].
From the filings
Quoted directly from source documents.
Cash and investments position as of June 30, 2026
“As of June 30, 2026, we had approximately $24.8 million of cash, cash equivalents and investments available-for-sale, and net working capital of $25.2 million.”
SEC MD&A · August 13, 2026
Management's belief in sufficient funds for twelve months
“management believes the Company currently has sufficient funds to meet its operating requirements for at least the next twelve months from the date of the filing of this report.”
SEC MD&A · August 13, 2026
Long-term funding dependence on growth strategy and profitability
“We believe our ability to fund our activities in the long term will be highly dependent upon (i) our ability to execute on the growth strategy of our hemodialysis concentrates business and maintain sales with existing customers, (ii) our ability to achieve sustained profitability and (iii) our ability to identify, develop, in-license, or acquire new products in developing our product portfolio.”
SEC MD&A · August 13, 2026
Risk of curtailment or cessation if unable to raise capital
“If we are unsuccessful in executing our business plan and we are unable to raise the required capital, we may be forced to curtail all of our activities and, ultimately, cease operations.”
SEC MD&A · March 26, 2026
Risks & what to watch (4)›
Key risks
- Ongoing net losses — Net loss of $1.2M for six months ended June 30, 2026; accumulated deficit persists [latest reported financials (as of 2026-06-30)].
- Dependence on capital raising — Long-term funding requires additional capital; no assurance of acceptable terms or availability [sec_mda · as of 2026-08-13].
- Execution risk on growth strategy — Success depends on hemodialysis concentrates growth, profitability, and product portfolio development [sec_mda · as of 2026-08-13].
- ATM facility limitations — ATM facility has $13.1M remaining but subject to market conditions and limitations [sec_mda · as of 2026-05-07].
What to watch
- Quarterly revenue and net income trends to assess progress toward sustained profitability [latest reported financials (as of 2026-06-30)].
- Updates on the company's ability to raise capital through its ATM facility or other financings [sec_mda · as of 2026-05-07].
- Execution of the hemodialysis concentrates growth strategy, including new customer acquisitions and margin improvements [sec_mda · as of 2026-08-13].
- Any strategic transactions, such as alliances, collaborations, or mergers, that could affect long-term funding [sec_mda · as of 2026-08-13].
Sources: SEC MD&A · Generated August 25, 2026 · How we verify sources →
Run ROCKWELL MEDICAL, INC. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available ROCKWELL MEDICAL, INC. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 2 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
Profitable (positive operating cash flow)
D/E 0.61 · 0% dilution
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
40
Total value held
$4.2M
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 2,364,722 | $2.1M |
| renaissance technologies llc | 639,120 | $571K |
| geode capital management, llc | 429,180 | $383K |
| blackrock, inc. | 236,671 | $211K |
| vanguard fiduciary trust co | 231,258 | $207K |
| northern trust corp | 104,523 | $93K |
| state street corp | 100,904 | $90K |
| jane street group, llc | 78,956 | $71K |
| perkins capital management inc | 70,371 | $63K |
| panagora asset management inc | 69,726 | $62K |
Showing top 10 of 40 institutional holders of ROCKWELL MEDICAL, INC.. Open the full 13F history after sign-in.
Short Interest
as of May 22, 2026- % of float
- 1.0%
- Days to cover
- 2.0
- Shares short
- 387,448
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
RMTI short interestGovernance
Frequently asked questions
What is the AI investment thesis for ROCKWELL MEDICAL, INC.?
Rockwell Medical, Inc. is a commercial-stage company focused on hemodialysis concentrates, with a recent net loss and a cash position management believes sufficient for at least twelve months.
Who is the CEO of ROCKWELL MEDICAL, INC.?
Dr. Mark Strobeck Ph.D. is the chief executive officer of ROCKWELL MEDICAL, INC. (RMTI).
Where is ROCKWELL MEDICAL, INC. headquartered?
ROCKWELL MEDICAL, INC. (RMTI) is headquartered in Wixom, MI, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.